Skip to Content

Join the 'Vemlidy' group to help and get support from people like you.

Vemlidy News

HIV Treatment Protects Uninfected Partner From the Virus

Posted 26 Jul 2017 by Drugs.com

TUESDAY, July 25, 2017 – HIV treatment prevented transmission of the virus in gay couples when only one partner had the virus, a new study shows. The research included 358 such gay couples in Australia, Brazil and Thailand. The HIV-positive partners received treatment that reduced the amount of virus in the blood to undetectable levels. The participants were followed from 2012 to 2016. During that time, the couples reported nearly 17,000 instances of anal intercourse without a condom. None resulted in HIV transmission, the study authors said. "Undetectable virus level effectively prevents HIV transmission among gay couples," said chief study investigator Andrew Grulich, a professor at the Kirby Institute at the University of New South Wales in Australia. "This is life-changing news for couples of differing HIV status. But it is important that the HIV positive partner is under regular ... Read more

Related support groups: HIV Infection, Tamiflu, Pre-Exposure Prophylaxis, Incivek, Truvada, Baraclude, Victrelis, Oseltamivir, Viread, Kaletra, Tenofovir, Entecavir, Norvir, Prezista, Lamivudine, Telaprevir, Ritonavir, Nevirapine, Boceprevir, Reyataz

Meds by Monthly Injection Might Revolutionize HIV Care

Posted 24 Jul 2017 by Drugs.com

MONDAY, July 24, 2017 – Getting a shot of medication to control HIV every month or two instead of having to take pills every day could transform the way the virus is kept at bay. New research suggests that injectable, long-acting antiretroviral therapy for HIV is as safe and effective as oral medications. The injection – given every four or eight weeks – includes the drugs cabotegravir and rilpivirine. "We have made considerable advances in the treatment of HIV over the last several decades," said study lead author Dr. David Margolis. "But for many patients living with HIV, it still remains a challenge to take daily oral medication, either because they are unable to or they choose not to. So it is important to find alternatives." Margolis is medical director of ViiV Healthcare in Research Triangle Park, N.C., the developer of this new approach and the company that funded the trial. ... Read more

Related support groups: HIV Infection, Pre-Exposure Prophylaxis, Incivek, Truvada, Baraclude, Victrelis, Viread, Kaletra, Entecavir, Norvir, Tenofovir, Lamivudine, Prezista, Telaprevir, Nevirapine, Reyataz, Ritonavir, Boceprevir, Norvir Soft Gelatin, Abacavir

Wider Access to Meds Cuts Global AIDS Deaths in Half

Posted 20 Jul 2017 by Drugs.com

THURSDAY, July 20, 2017 – AIDS-related deaths worldwide have been halved since 2005 as more people were able to get lifesaving drugs, UNAIDS (a United Nations Program) says in a new report. In 2016, 19.5 million (53 percent) of the almost 37 million people living with HIV (the virus that causes AIDS) had access to HIV treatment. AIDS-related deaths fell from 1.9 million in 2005 to 1 million in 2016. If the treatment trend continues, the goal to provide drugs for 30 million HIV patients by 2020 will be achieved, according to the report. "We met the 2015 target of 15 million people on treatment and we are on track to double that number to 30 million and meet the 2020 target," said Michel Sidibe, executive director of UNAIDS. "We will continue to scale up to reach everyone in need and honor our commitment of leaving no one behind," Sidibe said in a program news release. The greatest ... Read more

Related support groups: HIV Infection, Tamiflu, Atripla, Pre-Exposure Prophylaxis, Incivek, Truvada, Stribild, Complera, Baraclude, Victrelis, Oseltamivir, Viread, Kaletra, Norvir, Tenofovir, Entecavir, Telaprevir, Prezista, Lamivudine, Boceprevir

Could a Monetary Perk Help Keep HIV Patients on Their Meds?

Posted 22 Jun 2017 by Drugs.com

WEDNESDAY, June 21, 2017 – There are mixed results from a new study on the use of monetary rewards to help boost the odds that HIV-infected patients will enter care, and take their meds as directed. The study, conducted at HIV clinics in New York City and Washington, D.C., found that financial incentives such as gift cards could improve the likelihood that HIV patients would take antiretroviral medications that suppress the AIDS-causing virus. But the effect was modest in patients already receiving care, and the gift cards had little effect on increasing the number of new HIV-positive patients who got treated, the study authors said. Still, lead author Dr. Wafaa El-Sadr called the results "encouraging" and said they "should motivate efforts to pursue the further assessment of using financial incentives in HIV treatment programs and to determine their potential impact when scaled up." ... Read more

Related support groups: Harvoni, HIV Infection, Atripla, Pre-Exposure Prophylaxis, Incivek, Truvada, Epclusa, Triumeq, Stribild, Complera, Zepatier, Genvoya, Baraclude, Victrelis, Viread, Viekira Pak, Kaletra, Norvir, Entecavir, Tenofovir

6 Experts Resign from President's HIV/AIDS Advisory Panel in Protest

Posted 19 Jun 2017 by Drugs.com

Six experts resigned from the Presidential Advisory Council on HIV/AIDS because Donald Trump "simply does not care," one of the members wrote in an op/ed piece in Newsweek. Scott Schoettes, counsel and HIV Project Director at Lambda Legal, and five other members resigned on June 13. The council provides advice, information, and recommendations to the Secretary of Health and Human Services to promote effective treatment, prevention, and an eventual cure for HIV. However, as "advocates for people living with HIV, we have dedicated our lives to combating this disease and no longer feel we can do so effectively within the confines of an advisory body to a president who simply does not care," Schoettes wrote in the article published June 16. "The Trump Administration has no strategy to address the on-going HIV/AIDS epidemic, seeks zero input from experts to formulate HIV policy, and – most ... Read more

Related support groups: HIV Infection, Pre-Exposure Prophylaxis, Truvada, Baraclude, Viread, Tenofovir, Entecavir, Lamivudine, Nevirapine, Zidovudine, Epivir, Abacavir, Hepsera, Didanosine, Sustiva, Intelence, Telbivudine, Efavirenz, Ziagen, Edurant

Americans With HIV Staying on Lifesaving Meds Longer

Posted 31 May 2017 by Drugs.com

WEDNESDAY, May 31, 2017 – More Americans with HIV are sticking with medications that turn a fatal disease into a manageable condition, a new study shows. "This represents a lot of people who are not dying and not infecting others," said study corresponding author Ira Wilson, chair of Brown University's Health Services Policy and Practice Department, in Providence, R.I. "These differences represent tremendous, very real benefit," he added in a university news release. While there have been significant increases in how long HIV patients take their medications, many people still stop taking the drugs after a few years, the researchers cautioned. In the study, the researchers analyzed data from nearly 43,600 Medicaid patients in 14 states from 2001 to 2010, and found the length of time patients kept taking antiretroviral medications increased more than 50 percent. In 2001-2003, half of ... Read more

Related support groups: Harvoni, HIV Infection, Atripla, Pre-Exposure Prophylaxis, Incivek, Truvada, Epclusa, Stribild, Triumeq, Zepatier, Complera, Genvoya, Baraclude, Victrelis, Viread, Kaletra, Viekira Pak, Norvir, Tenofovir, Entecavir

Charlie Sheen's 2015 HIV Disclosure Spiked Use of Home Test Kits

Posted 18 May 2017 by Drugs.com

THURSDAY, May 18, 2017 – Soon after actor Charlie Sheen revealed his HIV-positive status back in late 2015, rates of at-home testing for the virus shot up to record levels, a new report shows. The study follows on 2016 research that found the the Internet was abuzz with millions more searches for HIV-related topics after the former "Two and a Half Men" star made the disclosure in November of 2015. In total, all English-language searches about HIV quadrupled beyond the usual number the day after Sheen's announcement, said a team from San Diego State University. Searches for information about HIV symptoms and testing were about six times higher than normal. And their follow-up research has now found that weekly sales of the HIV home-test kit OraQuick nearly doubled in the week after the announcement. "Charlie Sheen's disclosure is potentially the most significant domestic HIV prevention ... Read more

Related support groups: HIV Infection, Valtrex, Acyclovir, Pre-Exposure Prophylaxis, Valacyclovir, Ribavirin, Incivek, Zovirax, Baraclude, Famciclovir, Victrelis, Famvir, Daklinza, Viread, Kaletra, Entecavir, Ribasphere, Diagnosis and Investigation, Ganciclovir, Valcyte

Is the AIDS Epidemic Winding Down in the U.S.?

Posted 17 May 2017 by Drugs.com

WEDNESDAY, May 17, 2017 – Could the United States be turning the corner on the AIDS epidemic? New research suggests it's possible. If certain targets are met, the rate of new infections may be down to 12,000 a year by 2025, which would mark a transition toward the end of the HIV/AIDS epidemic, the researchers said. "Achieving these targets will require a sustained and intensified national commitment to ending the epidemic," said study author Dr. Robert Bonacci, from Brigham and Women's Hospital in Boston. "But if the U.S. does achieve a reduction to 12,000 new HIV infections by 2025, it could mark an important turning point in the U.S. HIV epidemic: a decline in the total number of people living with HIV in the U.S., and the beginning of the end of the U.S. AIDS epidemic," he said in a hospital news release. It's crucial that the goals of the U.S. National HIV/AIDS Strategy (NHAS) are ... Read more

Related support groups: HIV Infection, Pre-Exposure Prophylaxis, Incivek, Baraclude, Victrelis, Viread, Kaletra, Tenofovir, Norvir, Entecavir, Telaprevir, Prezista, Lamivudine, Boceprevir, Reyataz, Nevirapine, Ritonavir, Norvir Soft Gelatin, Hepsera, Abacavir

Life Expectancy With HIV Nears Normal With Treatment

Posted 11 May 2017 by Drugs.com

WEDNESDAY, May 10, 2017 – Young adults with HIV who get treatment are living longer in North America and Europe, a new study finds. In fact, a 20-year-old with HIV who began antiretroviral treatment in 2008 or later and had a low viral load after a year of treatment has a life expectancy that's close to that of the general population – around 78 years old, the study found. But life expectancy for people with HIV mostly remains lower than that of the general population, according to the study published in The Lancet HIV. The researchers said their findings could help reduce stigmatization of people with HIV and help them get jobs and medical insurance. The study should also encourage newly diagnosed HIV patients to begin treatment as soon as possible and stick with it. "Our research illustrates a success story of how improved HIV treatments coupled with screening, prevention and ... Read more

Related support groups: HIV Infection, Valtrex, Acyclovir, Tamiflu, Pre-Exposure Prophylaxis, Valacyclovir, Ribavirin, Incivek, Zovirax, Baraclude, Famciclovir, Victrelis, Famvir, Oseltamivir, Viread, Kaletra, Valcyte, Entecavir, Tenofovir, Norvir

FDA Approves Gilead’s Vemlidy (tenofovir alafenamide) for the Treatment of Chronic Hepatitis B Virus Infection

Posted 15 Nov 2016 by Drugs.com

FOSTER CITY, Calif.--(BUSINESS WIRE)--Nov. 10, 2016-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Vemlidy (tenofovir alafenamide, TAF) 25mg, a once-daily treatment for adults with chronic hepatitis B virus (HBV) infection with compensated liver disease. Vemlidy has a boxed warning in its product label regarding the risks of lactic acidosis/severe hepatomegaly with steatosis and post-treatment severe acute exacerbation of hepatitis B. See below for important safety information. Vemlidy is a novel, targeted prodrug of tenofovir that has demonstrated antiviral efficacy similar to and at a dose less than one-tenth that of Gilead’s Viread® (tenofovir disoproxil fumarate, TDF) 300mg. Data show that because Vemlidy has greater plasma stability and more efficiently delivers tenofovir to hepatocytes compared to Viread, it ca ... Read more

Related support groups: Hepatitis B, Viread, Tenofovir, Vemlidy, Tenofovir Alafenamide

Ask a Question

Further Information

Related Condition Support Groups

Hepatitis B

Vemlidy Patient Information at Drugs.com